Skip to main content
Delfa

← All assets

Senicapoc

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

1

Completed

0

Sites

2

Countries

1

Endpoints

19

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 19 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1

Trials by status

Recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
6
Global cognition
3
Executive function / language
3
Neuroimaging
3
Memory
2
Amyloid biomarkers
1
Fluid / digital biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 3 of 19 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

1

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

1

Montreal Cognitive Assessment (MoCA)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
SenicapocSenicapoc in Alzheimer's Disease

Senicapoc

Alzheimer’s disease, MCI / preclinical Alzheimer’s

mild AD dementiaPh 2Recruiting2Jun 2026-

Showing 1-1 of 1 trials